Recent updates from the phase 2 KRYSTAL‐7 (NCT04613596) trial have shown that the combination of pembrolizumab (Keytruda) and adagrasib (Krazati) exhibits promising efficacy and a manageable safety profile in patients with KRASG12C‐mutant NSCLC, particularly in those with a PD‐L1 tumour proportion score ≥50%. This evidence concerns the gene CD274 and neoplasm.